Results of a worldwide survey on the currently used histopathological diagnostic criteria for invasive lobular breast cancer-Reference-Cited by-同舟云学术

Results of a worldwide survey on the currently used histopathological diagnostic criteria for invasive lobular breast cancer

Published:2022-12 Issue:12 Volume:35 Page:1812-1820
ISSN:0893-3952
Container-title:Modern Pathology
language:en
Short-container-title:Modern Pathology

Author:

De Schepper Maxim,Vincent-Salomon Anne^ORCID,Christgen Matthias^ORCID,Van Baelen Karen,Richard François^ORCID,Tsuda Hitoshi,Kurozumi Sasagu,Brito Maria Jose,Cserni Gabor^ORCID,Schnitt Stuart^ORCID,Larsimont Denis,Kulka Janina,Fernandez Pedro Luis,Rodríguez-Martínez Paula,Olivar Ana Aula,Melendez Cristina,Van Bockstal Mieke^ORCID,Kovacs Aniko,Varga Zsuzsanna^ORCID,Wesseling Jelle^ORCID,Bhargava Rohit^ORCID,Boström Pia,Franchet Camille,Zambuko Blessing^ORCID,Matute Gustavo,Mueller Sophie,Berghian Anca,Rakha Emad,van Diest Paul J.^ORCID,Oesterreich Steffi^ORCID,Derksen Patrick W.B.^ORCID,Floris Giuseppe^ORCID,Desmedt Christine^ORCID

Funder

Eli Lilly and Company

F. Hoffmann-La Roche Ltd | Chugai Pharmaceutical

Takeda Pharmaceutical Company

Daiichi Sankyo Company

Taiho Pharmaceutical

Merck & Co., Inc. | MSD K.K.

NOVARTIS Foundation (Japan) for the Promotion of Science (NOVARTIS Foundation

Pfizer

Roche

KWF Kankerbestrijding

ZonMw